Fate Therapeutics Inc (FATE)

02:49 AM

What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional

02:49 AM

Jul 24, 2025

How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser

Jul 24, 2025

Jul 23, 2025

What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com

Jul 23, 2025

Jul 18, 2025

why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser

Jul 18, 2025

Jul 16, 2025

what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 16, 2025

Jul 16, 2025

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN

Jul 16, 2025

Jul 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World

Jul 16, 2025

Jul 15, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025

Jul 15, 2025

What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025

Jul 14, 2025

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance

Jul 14, 2025

Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025

Jul 05, 2025

Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World

Jul 05, 2025

Jul 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 03, 2025

Jul 03, 2025

Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest

Jul 03, 2025

Jul 02, 2025

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com

Jul 02, 2025

Jun 30, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener

Jun 30, 2025

Jun 28, 2025

Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jun 28, 2025

Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025

Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025

Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025

Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025

Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025

Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025

Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025

Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025

Jun 11, 2025

Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus

Jun 11, 2025

Jun 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times

Jun 11, 2025

Jun 11, 2025

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Jun 11, 2025

Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients - Investing.com

Jun 11, 2025